ABSTRACT
Pseudoporphyria is a photodistributed bullous disorder that is clinically and histologically similar to porphyria cutanea tarda (PCT), but without abnormal porphyrin biochemistry. Renal failure, dialysis, excessive ultraviolet A and medications, particularly nonsteroidal anti-inflammatory drugs (NSAIDs), have been associated with pseudoporphyria. We report a case of diclofenac-induced pseudoporphyria in a man with psoriatic arthritis. To our knowledge, this is only the second reported case of pseudoporphyria associated with diclofenac. Diclofenac has hitherto been considered by many dermatologists as a safe alternative in NSAID-induced pseudoporphyria.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Diclofenac/adverse effects , Drug Eruptions/etiology , Porphyrias/chemically induced , Adult , Humans , MaleSubject(s)
Carcinoma, Squamous Cell/pathology , Lichen Sclerosus et Atrophicus/drug therapy , Precancerous Conditions/pathology , Skin Neoplasms/pathology , Tacrolimus/therapeutic use , Vulvar Diseases/drug therapy , Administration, Topical , Carcinoma, Squamous Cell/diagnosis , Diagnosis, Differential , Female , Humans , Lichen Sclerosus et Atrophicus/pathology , Risk Assessment , Skin Neoplasms/diagnosis , Vulvar Diseases/pathologySubject(s)
Amyloidosis/pathology , Skin Diseases/pathology , Disease Progression , Humans , Leg Dermatoses/pathology , Male , Middle AgedABSTRACT
The recent Dermatological Care Working Group report highlighted important deficiencies in the dermatology service in the UK and recommended that care should move closer to the patient. The report stated that 'expert patients' could become 'sharers in their care' and are best placed to improve their own self management. One area that could benefit greatly from increased patient education and participation is the use of emollients. Emollients are frequently prescribed for patients with eczema and other dry skin conditions. Although the benefits of emollient therapy are widely accepted, prescribing practices vary considerably, often according to physicians' individual preferences. Patients can receive confusing or conflicting treatment advice, leading to frustration, non-compliance, and difficulty in following an effective regimen. To promote the effective use of emollients it is important for patients and health professionals to understand the functions of the skin and the principles of emollient use and application. We propose a set of simple guidelines for emollient therapy in eczema care to improve day-to-day management by health professionals in the community and to promote consistent practices by patients. These guidelines form the ABC dry skin and eczema management programme supported by the National Eczema Society and accredited by the British Skin Foundation.
